These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23393185)

  • 21. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.
    Koehler G; Heller S; Korsatko S; Roepstorff C; Rasmussen S; Haahr H; Pieber TR
    Diabetologia; 2014 Jan; 57(1):40-9. PubMed ID: 24057153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
    Rodbard HW; Cariou B; Zinman B; Handelsman Y; Philis-Tsimikas A; Skjøth TV; Rana A; Mathieu C;
    Diabet Med; 2013 Nov; 30(11):1298-304. PubMed ID: 23952326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial.
    Cindro PV; Krnić M; Modun D; Smajić B; Vuković J
    BMC Endocr Disord; 2021 Apr; 21(1):86. PubMed ID: 33926446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
    Heise T; Tack CJ; Cuddihy R; Davidson J; Gouet D; Liebl A; Romero E; Mersebach H; Dykiel P; Jorde R
    Diabetes Care; 2011 Mar; 34(3):669-74. PubMed ID: 21285389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
    Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
    Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
    Sorli C; Warren M; Oyer D; Mersebach H; Johansen T; Gough SC
    Drugs Aging; 2013 Dec; 30(12):1009-18. PubMed ID: 24170235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
    Norwood P; Chen R; Jaeckel E; Lingvay I; Jarlov H; Lehmann L; Heller S
    Diabetes Obes Metab; 2017 Nov; 19(11):1562-1569. PubMed ID: 28417535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
    Davies M; Sasaki T; Gross JL; Bantwal G; Ono Y; Nishida T; Tojjar D; Seino H
    Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
    Thalange N; Deeb L; Iotova V; Kawamura T; Klingensmith G; Philotheou A; Silverstein J; Tumini S; Ocampo Francisco AM; Kinduryte O; Danne T
    Pediatr Diabetes; 2015 May; 16(3):164-76. PubMed ID: 25683037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
    Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
    Onishi Y; Iwamoto Y; Yoo SJ; Clauson P; Tamer SC; Park S
    J Diabetes Investig; 2013 Nov; 4(6):605-12. PubMed ID: 24843715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
    Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.
    Rodbard HW; Cariou B; Zinman B; Handelsman Y; Wolden ML; Rana A; Mathieu C
    Diabetes Obes Metab; 2014 Sep; 16(9):869-72. PubMed ID: 24495158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.